What: Shares of Array BioPharma (NASDAQ:ARRY), a cancer-focused clinical-stage biotech, are down more than 22% as of 1:30 p.m. EDT today. The reason is that AstraZeneca (NYSE:AZN) released disappointing late-stage clinical trial results for selumetinib, a compound that it licensed from Array.
So what: AstraZeneca announced results from its phase 3 SELECT-1 trial, which was testing selumetinib in combination with chemotherapy as a potential second-line treatment in non-small cell lung cancer. Unfortunately, data showed that selumetinib failed to meet its primary endpoint of progression-free survival, and it also had no effect on overall survival.
This trial was one of Array's most advanced programs, so the disappointing news caused traders to bail on the company's shares today.
Now what: Selumetinib is also being researched as a potential treatment for thyroid cancer and for neurofibromatosis type 1, a genetic disorder that causes tumors to grow along nerve tissue. Both of these programs are ongoing, but seeing this news today provides investors with more reason to be cautious about their potential.
So far Array has earned more than $26 million in up-front and milestone payments from AstraZeneca, and it was slated to earn up to $70 million more plus royalties on product sales if everything worked out. Given the clinical failure of selumetinib in this lung cancer trial, it looks like Array has lost a large portion of that potential revenue.
We won't have more information about selumetinib's future in treating thyroid cancer and neurofibromatosis until those studies wrap up, which likely won't happen until late 2017. With new questions in the air about selumetinib's potential, it's not hard to understand why investors are bailing on Array's shares today.
Brian Feroldi has no position in any stocks mentioned. Like this article? Follow him on Twitter where he goes by the handle @Longtermmindset or connect with him on LinkedIn to see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.